MSD's etanercept, BRENZYS, will become the first biosimilar listed with new uptake drivers on 1 December.

New Stories
-
Mayne officially opens US facility
April 20, 2018 - - Latest News -
The question is how and why now?
April 20, 2018 - - Latest News -
New report show rebates average 44% in New Zealand
April 20, 2018 - - Latest News -
Merck sells consumer health business
April 20, 2018 - - Latest News -
Shire rejects third bid from Takeda
April 20, 2018 - - Latest News -
PBS listing process descends into farce
April 19, 2018 - - Latest News -
A serious industry deserving of serious decisions
April 19, 2018 - - Comment